263 related articles for article (PubMed ID: 30472601)
1. Therapeutic potential of selective histone deacetylase 3 inhibition.
Zhang L; Chen Y; Jiang Q; Song W; Zhang L
Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
[TBL] [Abstract][Full Text] [Related]
2. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Adhikari N; Jha T; Ghosh B
J Med Chem; 2021 Jul; 64(13):8827-8869. PubMed ID: 34161101
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Gediya P; Parikh PK; Vyas VK; Ghate MD
Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Sarkar R; Banerjee S; Amin SA; Adhikari N; Jha T
Eur J Med Chem; 2020 Apr; 192():112171. PubMed ID: 32163814
[TBL] [Abstract][Full Text] [Related]
5. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Qin HT; Li HQ; Liu F
Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
[TBL] [Abstract][Full Text] [Related]
6. The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.
Cao F; Zwinderman MRH; Dekker FJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498635
[TBL] [Abstract][Full Text] [Related]
7. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.
Felice C; Lewis A; Armuzzi A; Lindsay JO; Silver A
Aliment Pharmacol Ther; 2015 Jan; 41(1):26-38. PubMed ID: 25367825
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
Xu Z; Tong Q; Zhang Z; Wang S; Zheng Y; Liu Q; Qian LB; Chen SY; Sun J; Cai L
Clin Sci (Lond); 2017 Aug; 131(15):1841-1857. PubMed ID: 28533215
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.
Weïwer M; Lewis MC; Wagner FF; Holson EB
Future Med Chem; 2013 Sep; 5(13):1491-508. PubMed ID: 24024943
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
Kollar J; Frecer V
Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
Batchu SN; Brijmohan AS; Advani A
Clin Sci (Lond); 2016 Jun; 130(12):987-1003. PubMed ID: 27154743
[TBL] [Abstract][Full Text] [Related]
13. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
14. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
15. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Feb; 243():117278. PubMed ID: 31926248
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylases in cardiovascular and metabolic diseases.
Bagchi RA; Weeks KL
J Mol Cell Cardiol; 2019 May; 130():151-159. PubMed ID: 30978343
[TBL] [Abstract][Full Text] [Related]
18. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection.
Wagner FF; Lundh M; Kaya T; McCarren P; Zhang YL; Chattopadhyay S; Gale JP; Galbo T; Fisher SL; Meier BC; Vetere A; Richardson S; Morgan NG; Christensen DP; Gilbert TJ; Hooker JM; Leroy M; Walpita D; Mandrup-Poulsen T; Wagner BK; Holson EB
ACS Chem Biol; 2016 Feb; 11(2):363-74. PubMed ID: 26640968
[TBL] [Abstract][Full Text] [Related]
19. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
20. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.
Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R
Cells; 2021 May; 10(6):. PubMed ID: 34071497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]